Chronic renal dysfunction following liver transplantation

Clinical Transplantation

Volumn 22, Issue 3, 2008, Pages 333-340

  Schmitz, Volker ^a   Laudi, Sven ^a   Moeckel, Franziska ^a   Puhl, Gero ^a   Stockmann, Martin ^a   Tran, Zung Vu ^b   Kahl, Andreas ^a   Neumann, Ulf ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Immmunsuppression; Liver transplantation; Renal dysfunction; Risk factors

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HUMAN; KIDNEY DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETRANSPLANTATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME;

CALCINEURIN; CREATININE; CYCLOSPORINE; DIABETES COMPLICATIONS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 43749097658     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00806.x     Document Type: Article

References (32)

1. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998: 66: 59.
2. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
3. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994: 58: 170.
4. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001: 357: 587.
5. Jain AB, Venkataramanan R, Fung J et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. Transplant Proc 1991: 23: 2777.
6. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001: 72: 1934.
7. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
8. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: The problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001: 71(11 Suppl): SS42.
9. Bennett WM, Burdmann E, Andoh T, Elzinga L, F ranceschini N. Nephrotoxicity of immunosuppressive drugs. Miner Electrolyte Metab 1994: 20: 214.
10. Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephrotoxicity: How does it affect renal allograft function and transplant morphology? Transplant Proc 2004: 36(2 Suppl): 251S.
11. Raimondo ML, Dagher L, Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003: 75: 186.
12. Pfitzmann R, Klupp J, Langrehr JM et al. Mycophenolate mofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003: 76: 130.
13. Jain A, Venkataramanan R, Eghtesad B et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005: 80: 859.
14. Herrero JI, Quiroga J, Sangro B et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999: 5: 414.
15. C hristians U, R eisdorph N, K lawitter J, S chmitz V. Biomarkers of immunosuppressive drug toxicity. Curr Opin Organ Transplant 2005: 10: 284.
16. Rosner B. Fundamentals of Biostatistics, 6th Edition. Duxbury Press: Pacific Grove, CA, 2006.
17. McCauley J, Van Thiel DH, Starzl TE, P uschett JB. Acute and chronic renal failure in liver transplantation. Nephron 1990: 55: 121.
18. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Experimental and clinical observations. Semin Nephrol 1997: 17: 34.
19. Hernandez-Herrera G, Castillo DD, Perez R, Lopez-Rubio F, Aljama P. Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. Transpl Int 1998: 11(Suppl 1): S104.
20. Morris-Stiff GJ, Baboolal K, Dunstan F, Jurewicz WA. Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: Results of an observational study. Transpl Int 1999: 12: 288.
21. Zhang W, Li JL, Hosaka M et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci USA 2000: 97: 9765.
22. Nielsen FT, Ottosen P, Starklint H, Dieperink H. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003: 18: 491.
23. Trompeter R, Filler G, Webb NJ et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002: 17: 141.
24. Waller JR, Murphy GJ, Metcalfe MS, Stanford RM, Pattenden CJ, Nicholson ML. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. Transplant Proc 2002: 34: 1587.
25. Jain AB, Hamad I, Rakela J et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: An interim report. Transplantation 1998: 66: 1395.
26. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984: 311: 699.
27. Neau-Cransac M, Morel D, Bernard PH et al. Renal failure after liver transplantation: Outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002: 16: 368.
28. Chan CY, Das Gupta K, Baker AL. Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996: 24: 1085.
29. Sandborn WJ, Hay JE, Porayko MK et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994: 19: 925.
30. Aleksic I, Baryalei M, Busch T et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000: 69: 1586.
31. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999: 29: 1181.
32. Shockcor JP, Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2002: 2: 35.